| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S13126 R50053 |
Marks (Controls exposed to Bupropion), 2021 | Pulmonary Hypertension | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 7.44 [0.15;378.84] C | 0/55 0/406 | 0 | 55 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6080 R15821 |
Kieler, 2012 | Persistent pulmonary hypertension of the newborn | 2nd and/or 3rd trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: no or not specified | 2.80 [1.20;6.70] | 5/1,281 1,935/1,588,140 | 1,940 | 1,281 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5936 R15198 |
Chambers, 2006 | Persistent pulmonary hypertension of the newborn (PPHN) | 2nd and/or 3rd trimester | nested case control | unexposed (general population or NOS) | Adjustment: No Matched Monotherapy: no or not specified | 20.19 [1.08;375.92] C | 4/4 373/1,209 | 377 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 3.39 [1.51;7.61] | 2,317 | 1,340 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls exposed to Bupropion;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded